CCM
Consonance Capital Management Portfolio holdings
AUM
$7.28M
1-Year Return
42.86%
This Quarter Return
-11.41%
1 Year Return
-42.86%
3 Year Return
+319.33%
5 Year Return
+899.35%
10 Year Return
–
AUM
$1.36B
AUM Growth
-$498M
(-27%)
Cap. Flow
-$263M
Cap. Flow
% of AUM
-19.32%
Top 10 Holdings %
Top 10 Hldgs %
76.48%
Holding
31
New
2
Increased
13
Reduced
4
Closed
7
Top Buys
| 1 |
AMRN
Amarin Corp
AMRN
|
$61M |
| 2 |
Exelixis
EXEL
|
$54.4M |
| 3 |
United Therapeutics
UTHR
|
$26M |
| 4 |
uniQure
QURE
|
$24.5M |
| 5 |
Myriad Genetics
MYGN
|
$21M |
Top Sells
| 1 |
Puma Biotechnology
PBYI
|
$106M |
| 2 |
NVRO
NEVRO CORP.
NVRO
|
$82.4M |
| 3 |
Pacific Biosciences
PACB
|
$81.8M |
| 4 |
NUVA
NuVasive, Inc.
NUVA
|
$77.3M |
| 5 |
Verastem
VSTM
|
$37.4M |
Sector Composition
| 1 | Healthcare | 99.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Theravance Biopharma
TBPH
$703M
| – | – |
-731,909
| Closed | -$23.9M |
|
|
27
Verastem
VSTM
$663M
| – | – |
-429,519
| Closed | -$37.4M |
|
|
NVRO
28
DELISTED
NEVRO CORP.
NVRO
| – | – |
-1,446,333
| Closed | -$82.4M |
|
|
NUVA
29
DELISTED
NuVasive, Inc.
NUVA
| – | – |
-1,089,523
| Closed | -$77.3M |
|
|
RARX
30
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| – | – |
-1,454,761
| Closed | -$26.3M |
|